|

CDK4/6 inhibitor with endocrine therapy Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Peking University People's Hospital1

Indications

  • ctDNA Monitoring1
  • High-risk Breast Cancer1
  • HER2-negative Breast Cancer1
  • Hormone Receptor Positive Breast Cancer1
  • Early-stage Breast Cancer1

Other1 trial

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.